Company Description
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company.
It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies.
The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma.
Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
| Country | United States |
| Founded | 2011 |
| IPO Date | Jul 23, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 97 |
| CEO | Rachel Haurwitz |
Contact Details
Address: 2929 7th Street, Suite 105 Berkeley, California 94710 United States | |
| Phone | 510 982 6030 |
| Website | cariboubio.com |
Stock Details
| Ticker Symbol | CRBU |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 1619856 |
| CUSIP Number | 142038108 |
| ISIN Number | US1420381089 |
| Employer ID | 45-3728228 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Rachel E. Haurwitz Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| Sriram Ryali M.B.A. | Chief Financial Officer |
| Barbara G. McClung Esq., J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Jennifer A. Doudna Ph.D. | Co-founder and Member of Scientific Advisory Board |
| Ryan Fischesser | Interim Principal Accounting Officer and Controller |
| Timothy P. Kelly M.B.A. | Chief Technology Officer |
| Reigin Zawadzki | Chief People Officer |
| Ruhi A. Khan M.B.A. | Chief Business Officer |
| Dr. Tina Albertson M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 1, 2026 | DEFR14A | Filing |
| Apr 24, 2026 | ARS | Filing |
| Apr 24, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 10, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 31, 2026 | 8-K | Current Report |
| Mar 5, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 5, 2026 | 10-K | Annual Report |
| Mar 5, 2026 | 8-K | Current Report |
| Feb 25, 2026 | 144 | Filing |